| Cat. No. |
Product Name |
CAS No. |
Information |
| H8975 |
Vebicorvir
|
2090064-66-5 |
Vebicorvir is a first-generation hepatitis B virus (HBV) core protein inhibitor, has demonstrated effective antiviral activity. |
| H8956 |
Bulevirtide
|
2012558-47-1 |
Bulevirtide is an antiviral medication for the treatment of chronic hepatitis D (in the presence of hepatitis B);Bulevirtide works by attaching to and blocking a receptor (target) through which the hepatitis delta and hepatitis B viruses enter liver cells. By blocking the entry of the virus into the cells, it limits the ability of HDV to replicate and its effects in the body, reducing symptoms of the disease. |
| H4125 |
Selgantolimod
|
2004677-13-6 |
Selgantolimod (GS-9688,GS9688) is a potent and selective oral Toll-Like Receptor 8 agonist with (IL-12p40 EC50 = 220 nM) and >100-fold TLR7 selectivity (IFN-α EC50 > 50 μM) was observed in human peripheral blood mononuclear cells (PBMCs) for the treatment of chronic Hepatitis B. |
| H4062 |
Inarigivir soproxil
|
942123-43-5 |
Inarigivir soproxil (SB-9200, SB9200, Inarigivir, ORI-9020) is an orally bioavailable dinucleotide that activates RIG-I and NOD2, induces interferon mediated antiviral immune responses; shows broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, RSV and influenza, and also demonstrates activity HBV in vitro and in vivo; a novel agonist of innate immunity, and prodrug of Inarigivir (ORI-9020;SB-9000). |
| H1251 |
RO6889678
|
1578153-27-1 |
RO6889678 is a highly potent inhibitor of HBV capsid formation with attributes that are favorable for targeting the liver, whilst maintaining moderate peripheral exposure. |
| H1250 |
NVR 3-778
|
1445790-55-5 |
NVR 3-778 (NVR3-778, NVR 3778) is a small molecule inhibitor of HBV replication that targets the viral core protein, a first-in-class capsid assembly modulator; inhibits the generation of infectious HBV DNA containing virus particles with EC50 of 0.40 uM in HepG2.2.15 cells; NVR 3-778 inhibits pgRNA encapsidation, viral replication and the production of HBV DNA- and HBV RNA-containing particles, also inhibits de novo infection and viral replication in primary human hepatocytes with EC50 of 0.81 uM against HBV DNA and 3.7-4.8 uM against the production of HBV antigens and intracellular HBV RNA; demonstrates favorable pharmacokinetics and safety in animal species. |
| H1246 |
Isothiafludine
|
960527-22-4 |
Isothiafludine (NZ-4) is a novel HBV capsid assembly inhibitor that inhibits HBV replication through blocking pregenomic RNA encapsidation, suppresses HBV replication in HepG2.2.15 cells with IC50 of 1.33 uM; shows activity against the replication of various drug-resistant HBV mutants, including 3TC/ETV-dual-resistant and ADV-resistant HBV mutants; concentration-dependently reduces the encapsidated HBV pgRNA, resulting in the assembly of replication-deficient capsids in HepG2.2.15 cells; inhibits DHBV DNA replication in the DHBV-infected ducks after oral administration. |
| H1241 |
GLS4
|
1092970-12-1 |
GLS4 (Morphothiadin) is a potent inhibitor of HBV capsid assembly, inhibits HBV replication (EC50=62.24 nM) and reduces HBV-DNA levels in HepG.2.2.15 cells (IC50=14 nM), shows efficacy against ADV-resistant HBV mutations; strongly inhibits core gene expression (at 100 to 200 nM), suppresses virus accumulation in the supernantant of HepAD38 cells; inhibits HBV replicative forms in the live, shows strong and sustained suppression of virus DNA in treated mice.
Phase 3 Clinical |
| H1239 |
Besifovir
|
441785-26-8 |
Besifovir (PMCDG Dipivoxil, NA-380, LB-80380) is a potent, selective, orally available anti-HBV agent, the prodrug of PMCDG (EC50=4 uM).
Phase 3 Clinical |
| H1236 |
Bay 41-4109
|
298708-81-3 |
Bay 41-4109 is a potent, non-nucleosidic inhibitor of HBV nucleocapsid maturation with IC50 of 0.05 uM; reduces HBV core protein levels in cell culture, possess in vitro and in vivo antiviral activity. |
$ USD
Select Your Country or Region